NEWS: JANUARY 2007

01/12/2007-

Peregrine Pharmaceuticals Inc. establishes new subsidiary Peregrine Beijing Pharmaceuticals Technology Development Ltd. in Beijing, China.To read article click here.

-01/11/2007-

Schering-Plough Corporation terminates alliance with Valeant Pharmaceuticals Int. and Metabasis Therapeutics Inc. To read article click here.

-01/10/2007-

Illumina Inc. launches its new Human 1M BeadChip for whole-genome DNA analysis. To read article click here.

Imclone Systems Inc.'s Phase III clinical trials of its anti-cancer drug Erbitux show an increase survival rate in advanced colorectal cancer when combined with Folfiri. To read article click here.

-01/09/2007-

Illumina Inc. forms collaboration with the Mayo Clinic. To read article click here.

Genentech Inc. puchases oncology program from Amphora Discovery Corp. To read article click here.

Introgen Therapeutics Inc.'s INGN 241 acts synergistically with shock protein 90 (Hsp90) inhibitors. To read article click here.

Incyte Corp. announces positive clinical trial results of HIV and diabetes treatment candidates. To read article click here.

GlaxoSmithKline to acquire Praecis Pharmaceuticals Inc. To read article click here.

Biogen Idec begins Phase III clinical trials of BG-12 for multiple sclerosis treatment. To read article click here.

-01/08/2007-

Merck Serono S.A. is launched. To read article click here.

Seattle Genetics and Genentech form partnership for the development and commercialization of SGN-40 for cancer. To read article click here.

FDA approves Medimmune's FluMist nasal spray flu vaccine. To read article click here.

Targacept Inc. begins Phase I clinical trials of TC-2216 for the treatment of depression and anxiety disorders. To read article click here.

-01/05/2007-

Press Release: Genevac, world leader in solvent removal technologies, has chosen the forthcoming LabAutomation 2007 meeting (27th-31st January) to present its latest instrumentation solutions for productive and sample safe solvent drying. To read press release click here.

Provid Pharmaceuticals Inc. acquires Tripos Discovery Research. To read article click here.

Genentech Inc.'s experimental ovarian cancer drug Pertuzumab does not meet goal in Phase II clinical trials. To read article click here.

Merck acquires majority shareholding in Serono. To read article click here.

VaxGen Inc. to cut its work force by about 51 percent. To read article click here.

TargeGen Inc. moves forward its Jak2 inhibitor candidate TG101348 for clinical development. To read article click here.

IGI Inc. out-licenses drug delivery technology to Novavax Inc. for bird flu vaccine development. To read article click here.

OSI Pharmaceuticals grants rights of its Type-2 diabetes program and compounds to Eli Lilly. To read article click here.

-01/04/2007-

Press Release: Radleys have announced a new application report that describes how the Cooled Carousel 12 Reaction Station has enabled the Faculty of Natural Sciences, Comenius University (Bratislava, Slovakia) to improve the structure of novel chiral ligands used for Palladium catalysed allylic alkylation reactions. To read press release click here.

BioMarin Pharmaceutical Inc. begins Phase 2 clinical trials of 6R-BH4 for peripheral arterial disease treatment. To read article click here.

BioCryst Pharmaceuticals Inc. wins $102.6M bird flu drug federal contract. To read article click here.

Biogen Idec Inc. to acquire Syntonix Pharmaceuticals Inc. for $40 million. To read article click here.

Pharmacopeia Inc. and Wyeth Pharmaceuticals form JAK3 inhibition research collaboration for rheumatoid arthritis, psoriasis and other immunological conditions. To read article click here.

Sunesis Pharmaceuticals Inc. out-licenses its LFA-1 inhibitior program to SARcode Corporation. To read article click here.

Vical Inc. begins Phase III clinical trials of Allovectin-7® for metastatic melanoma treatment. To read article click here.

Nuvelo, Inc. begins Phase II clinical trials of recombinant nematode anticoagulant protein c2 (rNAPc2) for metastatic colorectal carcinoma treatment. To read article click here.

-01/03/2007-

Exelixis Inc. and Genentech Inc. form alliance to develop Exelixis' anti-cancer drug candidate XL518. To read article click here.

Ciphergen Biosystems and Quest Diagnostics to co-develop a test for peripheral artery disease. To read article click here.

Genaera Corp. to terminate the development for Evizon and cut 30% of its workforce. To read article click here.

Theravance Inc. begins Phase II clinical trials of TD-1792 for skin infections. To read article click here.

Cytokinetics Inc. and Amgen Inc. sign small-molecule research collaboration for heart failure. To read article click here.

ImClone Systems Inc. begins Phase I clinical trials of IMC-3G3 for solid tumor treatment. To read article click here.

Galapagos NV expands and extends drug discovery collaboration with Amgen Inc. To read article click here.

-01/02/2007-

Biomira Inc. begins Phase II clinical trials of PX-12 for pancreatic cancer treatment. To read article click here.

Eli Lilly closes manufacturing facility in the UK. To read article click here.